SCHEMBL19974874

SCHEMBL19974874

O=C(NC1CN(C(=O)C2CCC2)C1)C(=O)[C@H]1CCC(=O)N1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
CAPN1 P07384 3/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
F2R P25116 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176300 0.98 P2RX7 (0.43) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL19975374 0.88 P2RX7 (0.47) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL19974981 0.87 P2RX7 (0.49) P2RX7GAAKMT2ACAPN1ITGB1
SCHEMBL21183549 0.85 EPHX2 (0.50) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL21183578 0.85 P2RX7 (0.51) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL21183582 0.85 P2RX7 (0.51) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL21176249 0.84 P2RX7 (0.46) P2RX7GAAALDH1A1MEN1KMT2A
SCHEMBL21176193 0.82 ALDH1A1 (0.43) P2RX7GAAALDH1A1KMT2ATSHR
SCHEMBL21176322 0.82 GPR119 (0.44) P2RX7GAAKMT2ACAPN1
SCHEMBL21176161 0.82 DPP7 (0.54) P2RX7GAAMEN1KMT2ACAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885GAA 75/4885ALDH1A1 2271/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C P2RX7 564/4885GAA 107/4885ALDH1A1 2673/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885GAA 75/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.